Lipid Metabolism Dysregulation in Neurodegeneration

Lipid Metabolism Dysregulation in Neurodegeneration

Overview

Lipid metabolism dysregulation represents a critical pathological feature common to all major neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and Huntington's disease (HD). The brain, comprising approximately 50-60% lipids by dry weight, relies on sophisticated lipid homeostasis mechanisms for neuronal function, synaptic plasticity, myelination, energy metabolism, and cell signaling. Disruption of these mechanisms contributes to protein aggregation, oxidative stress, mitochondrial dysfunction, and ultimately neuronal death[@pugazhenthi2017].

The lipid metabolism pathway encompasses multiple interconnected systems: cholesterol homeostasis and trafficking, phospholipid and sphingolipid metabolism, fatty acid oxidation, ganglioside composition, and membrane raft integrity. Each of these systems is affected differently across neurodegenerative diseases, yet convergent pathways create opportunities for therapeutic intervention. The APOE gene, encoding apolipoprotein E, stands as the strongest genetic risk factor for late-onset AD and exemplifies the critical role of lipid metabolism in neurodegeneration[@chen2019].

This mechanism page provides a comprehensive analysis of lipid dysregulation across neurodegenerative diseases, integrating current knowledge of molecular mechanisms, key proteins, therapeutic targets, and cross-disease commonalities.

Lipid Metabolism Dysregulation in Neurodegeneration

Overview

Lipid metabolism dysregulation represents a critical pathological feature common to all major neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and Huntington's disease (HD). The brain, comprising approximately 50-60% lipids by dry weight, relies on sophisticated lipid homeostasis mechanisms for neuronal function, synaptic plasticity, myelination, energy metabolism, and cell signaling. Disruption of these mechanisms contributes to protein aggregation, oxidative stress, mitochondrial dysfunction, and ultimately neuronal death[@pugazhenthi2017].

The lipid metabolism pathway encompasses multiple interconnected systems: cholesterol homeostasis and trafficking, phospholipid and sphingolipid metabolism, fatty acid oxidation, ganglioside composition, and membrane raft integrity. Each of these systems is affected differently across neurodegenerative diseases, yet convergent pathways create opportunities for therapeutic intervention. The APOE gene, encoding apolipoprotein E, stands as the strongest genetic risk factor for late-onset AD and exemplifies the critical role of lipid metabolism in neurodegeneration[@chen2019].

This mechanism page provides a comprehensive analysis of lipid dysregulation across neurodegenerative diseases, integrating current knowledge of molecular mechanisms, key proteins, therapeutic targets, and cross-disease commonalities.

Historical Context and Discovery

The recognition of lipid metabolism abnormalities in neurodegeneration has evolved over several decades:

• 1980s-1990s: Initial observations of cholesterol alterations in AD brain tissue and the identification of APOE ε4 as an AD risk factor[@maslihan1995]
• 2000s: Discovery of sphingolipid abnormalities, ceramide elevation, and their pro-apoptotic effects[@cutler2004]
• 2010s: Understanding of APOE isoforms in lipid transport, Aβ clearance, and neuroinflammation[@barry2011]
• 2020s: Recognition of lipid droplet accumulation as a common feature across diseases, and the role of lipid metabolism in glia[@bartz2016]

Biochemical Pathways

Cholesterol Homeostasis

Cholesterol is essential for neuronal function, constituting a major component of neuronal membranes, myelin, and lipid rafts. The brain synthesizes cholesterol locally since circulating cholesterol cannot cross the blood-brain barrier. Key regulatory mechanisms include:

Synthesis and Regulation:

• SREBP2 (Sterol Regulatory Element-Binding Protein 2): Master transcription factor regulating cholesterol synthesis. In neurodegeneration, SREBP2 dysregulation leads to altered cholesterol production[@greitzer2014]
• LXR (Liver X Receptor): Nuclear receptor sensing oxysterols and promoting cholesterol efflux. LXR agonists show promise in AD models
• CYP27A1 (Cytochrome P450 27A1): Enzyme producing 27-hydroxycholesterol (27-OHC), an oxysterol elevated in AD and PD that crosses the blood-brain barrier and promotes neurotoxicity[@testa2016]

• APOE (Apolipoprotein E): Central lipid transport protein in the brain. Three common isoforms (APOE ε2, ε3, ε4) differ in lipid binding capacity and AD risk
• ABCA1 (ATP-Binding Cassette Transporter A1): Mediates cholesterol efflux to APOE. ABCA1 deficiency increases amyloid pathology
• ABCG1 (ATP-Binding Cassette Transporter G1): Works with ABCA1 for cholesterol efflux from cells
• LDLR (Low-Density Lipoprotein Receptor): Facilitates APOE-lipoprotein uptake

Phospholipid Metabolism

Phospholipids form the fundamental structure of cellular membranes. Abnormalities in phospholipid composition contribute to membrane dysfunction:

Key Phospholipids:

• Phosphatidylcholine (PC): Major membrane phospholipid reduced in AD brain
• Phosphatidylserine (PS): Important for apoptosis signaling; alterations affect neuronal survival
• Phosphatidylethanolamine (PE): Critical for membrane fusion and neurotransmitter release
• Phosphatidylinositol (PI): Key signaling molecule; PI metabolism impaired in PD

• PLA2 (Phospholipase A2): Releases fatty acids from phospholipids; elevated activity in AD contributes to inflammation
• PLD (Phospholipase D): Involved in membrane trafficking and autophagy

Sphingolipid Metabolism

Sphingolipids, including ceramides, gangliosides, and sulfatides, serve as critical signaling molecules and membrane components:

Ceramide Pathway:

• Serine palmitoyltransferase (SPT): Rate-limiting enzyme in ceramide synthesis
• Ceramidase (ASAH1): Catabolizes ceramides; reduced activity leads to ceramide accumulation
• Ceramide synthase (CERS): Produces ceramides from sphingosine and fatty acids

• GM1, GD1a, GT1b: Neuronal gangliosides affected in neurodegeneration
• GM1 binding to α-synuclein: Modulates aggregation kinetics in PD

Fatty Acid Metabolism

Fatty acids serve as energy substrates, membrane components, and signaling molecules:

β-Oxidation:

• Carnitine palmitoyltransferase (CPT): Rate-limiting enzyme in mitochondrial fatty acid oxidation
• PPARα/PPARγ: Nuclear receptors regulating fatty acid metabolism genes

• DHA (Docosahexaenoic Acid): Highly enriched in neuronal membranes; reduced in AD/PD
• EPA (Eicosapentaenoic Acid): Anti-inflammatory effects; supplementation trials ongoing
• Arachidonic Acid (AA): Pro-inflammatory; elevated in neurodegeneration

Membrane Raft Composition

Lipid rafts are cholesterol-rich microdomains concentrating signaling proteins:

Composition:

• Cholesterol and sphingolipids: Core raft components
• Flotillin proteins: Raft markers
• APP and BACE1: Concentrated in rafts for amyloidogenic processing

• Cholesterol elevation increases γ-secretase activity in rafts
• Raft disruption affects signal transduction
• Altered raft composition in aging and disease

Pathway Overview

Lipid Dysregulation in Specific Diseases

Alzheimer's Disease

Cholesterol Dysregulation:
Cholesterol metabolism is profoundly altered in AD. The APOE ε4 allele, present in approximately 15-20% of the population, represents the strongest genetic risk factor for late-onset AD. APOE ε4 has reduced lipid binding capacity compared to APOE ε3, leading to impaired cholesterol delivery to neurons[@chen2019]. This deficiency affects synaptic maintenance, Aβ clearance, and neuroinflammatory responses.

Elevated cholesterol in lipid rafts enhances amyloidogenic APP processing through γ-secretase. When cholesterol levels increase in these membrane microdomains, γ-secretase activity increases, producing more amyloidogenic Aβ peptides. Aβ itself can alter cholesterol metabolism in neurons and glia, creating a feed-forward pathological loop.

The oxysterol 27-hydroxycholesterol (27-OHC) is elevated in AD brain tissue and can cross the blood-brain barrier. 27-OHC promotes Aβ production, contributes to neurotoxicity, and is associated with cognitive decline. The enzyme CYP27A1, which produces 27-OHC, shows increased expression in AD brain[@testa2016].

Phospholipid Abnormalities:
Phospholipid alterations in AD include reduced phosphatidylcholine, phosphatidylserine, and phosphatidylethanolamine in brain tissue. These changes affect membrane fluidity, neurotransmitter release, and synaptic function. The phospholipase A2 (PLA2) enzyme shows elevated activity in AD, contributing to inflammatory lipid mediator production[@lini2004].

Sphingolipid Dysregulation:
Ceramide levels are elevated in AD brain, particularly in regions susceptible to neurodegeneration. Ceramides induce mitochondrial dysfunction, activate caspase pathways, and promote Aβ generation. The accumulation results from both increased synthesis and impaired catabolism. Ganglioside GM1 binds to Aβ and may influence aggregation kinetics[@van2020].

Fatty Acid Metabolism:
Reduced polyunsaturated fatty acids (PUFAs), particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are consistently observed in AD brain tissue, cerebrospinal fluid, and plasma. DHA is highly enriched in synaptic membranes where it plays critical roles in membrane fluidity, neurotransmitter release, and synaptic plasticity. The depletion of DHA in AD correlates with cognitive decline and contributes to synaptic dysfunction[@pugazhenthi2017].

Lipid Droplet Accumulation:
Lipid droplets accumulate in AD brain astrocytes and neurons. These lipid stores reflect impaired lipophagy and altered energy metabolism. The accumulation contributes to lipotoxicity and inflammatory responses.

Key Mechanisms:

• APOE ε4 impaired lipid transport and Aβ clearance
• Cholesterol-enhanced Aβ production in lipid rafts
• 27-OHC neurotoxicity and Aβ promotion
• PUFA (DHA/EPA) deficiency affecting synaptic function
• Ceramide-induced apoptosis and neuroinflammation

Parkinson's Disease

Cholesterol and Oxysterols:
Cholesterol and its oxidized metabolite 27-hydroxycholesterol are elevated in PD brain. 27-OHC is neurotoxic and can promote α-synuclein aggregation. The enzyme CYP27A1 is upregulated in PD brain, and this elevation correlates with disease severity. Cholesterol metabolism alterations affect α-synuclein clearance through the autophagy-lysosome pathway[@plotegher2020].

Sphingolipid Dysregulation:
Sphingolipid metabolism is significantly altered in PD. The protein α-synuclein binds to phospholipid membranes with high affinity, and lipid interactions modulate its aggregation kinetics. Membrane binding protects α-synuclein from aggregation, but certain lipid species, particularly those with saturated fatty acids, promote misfolding and oligomerization. Lipid peroxidation products accelerate α-synuclein aggregation, creating a feed-forward loop[@garciagonzalez2023].

Ganglioside GM1 shows altered expression in PD brain and modulates α-synuclein aggregation. The interaction between GM1 and α-synuclein represents a potential therapeutic target.

Fatty Acid Metabolism:
Fatty acid oxidation is impaired in PD, with reduced activity of mitochondrial fatty acid β-oxidation enzymes. This impairment contributes to energy deficits in dopaminergic neurons, which have high metabolic demands due to their pacemaking activity. PUFAs are reduced in PD brain and cerebrospinal fluid, and these deficiencies may contribute to neuronal vulnerability[@galvagnion2022].

Lipid Peroxidation:
Lipid peroxidation contributes significantly to oxidative stress in dopaminergic neurons. Dopaminergic neurons are particularly susceptible to oxidative damage because dopamine metabolism produces reactive oxygen species. The lipid peroxidation product 4-hydroxynonenal (4-HNE) is elevated in PD brain and forms toxic adducts with proteins.

Key Mechanisms:

• α-Synuclein-lipid membrane binding and aggregation modulation
• Cholesterol oxidation (27-OHC) neurotoxicity
• GM1 ganglioside alterations affecting α-synuclein
• PUFA deficiency and lipid peroxidation
• Impaired fatty acid β-oxidation

Amyotrophic Lateral Sclerosis

Lipid Droplet Accumulation:
ALS features prominent lipid droplet accumulation in neurons and glia. C9orf72 expansions, the most common genetic cause of ALS and FTD, localize to lipid droplets and affect lipophagy. The C9orf72 protein localizes to the lysosomal membrane and is involved in autophagic clearance of lipid droplets. Hexanucleotide repeat expansions lead to reduced C9orf72 protein levels, impairing this clearance function. Dipeptide repeat proteins produced from expanded repeats directly localize to lipid droplets, further disrupting lipid homeostasis[@bjorkqvist2018].

SOD1-Mediated Effects:
SOD1 mutations increase lipid peroxidation and disrupt lipid membrane composition. Mutant SOD1 interacts with lipid membranes, causing peroxidation and altering membrane fluidity. This membrane damage contributes to motor neuron vulnerability.

Myelin Lipid Dysfunction:
Motor neurons have large myelinated axons requiring extensive membrane maintenance. Myelin is approximately 70% lipids, including cholesterol and phospholipids. In ALS, myelin breakdown products accumulate, contributing to axonal degeneration. Oligodendrocyte dysfunction is present in ALS brain and spinal cord, with reduced myelin basic protein and other myelin markers[@rottenreich2022].

Key Mechanisms:

• C9orf72 and lipid droplet accumulation due to impaired lipophagy
• SOD1-mediated lipid peroxidation and membrane damage
• Myelin lipid defects affecting axonal integrity
• Oligodendrocyte dysfunction

Frontotemporal Dementia

Tau and Lipid Rafts:
FTD shows subtype-dependent lipid dysfunction. Tau mutations affect lipid raft composition and cholesterol transport. Tau can affect cholesterol synthesis and trafficking, and mutations disrupting tau function have downstream effects on lipid homeostasis. This is particularly relevant in frontal and temporal brain regions most affected in FTD.

TDP-43 and Lipid Metabolism:
TDP-43 pathology disrupts lipid-related gene expression. TDP-43 is an RNA-binding protein regulating alternative splicing of many genes, including those involved in lipid metabolism. In FTD and ALS, TDP-43 forms insoluble aggregates in the cytoplasm, losing nuclear function. This disrupts normal regulation of lipid metabolism genes.

Progranulin and Lysosomal Lipid Catabolism:
Progranulin haploinsufficiency impairs lysosomal lipid catabolism. Progranulin is mutated in approximately 20% of familial FTD cases. Reduced progranulin levels impair lysosomal function, which is critical for catabolizing lipid droplets through lipophagy. This leads to lipid droplet accumulation, similar to C9orf72 in ALS.

C9orf72 Overlap:
Patients with C9orf72 expansions may present with FTD, ALS, or both, showing similar lipid abnormalities. This overlap suggests lipid metabolism dysfunction is a key component of the disease mechanism.

Key Mechanisms:

• Tau-lipid raft disruption and cholesterol dysregulation
• TDP-43 transcriptional effects on lipid genes
• Progranulin-lysosomal pathway impairment
• C9orf72 expansion effects on lipid droplets

Huntington's Disease

Transcriptional Repression:
HD features profound lipid metabolism dysfunction through mutant huntingtin's effects on transcription. PPARγ downregulation suppresses lipid metabolism genes. Mutant huntingtin interferes with PPARγ transcriptional activity, reducing expression of genes involved in fatty acid oxidation, lipid transport, and energy metabolism[@kim2020].

Lipid Droplet Accumulation:
Lipid droplets accumulate in neurons and glia in HD. This accumulation is driven by impaired lipophagy, reduced fatty acid oxidation, and increased fatty acid synthesis. These lipid droplets actively interfere with cellular function, sequestering critical proteins and creating lipotoxic species.

Cholesterol and Neurosteroids:
Cholesterol synthesis is altered, reducing neuroprotective neurosteroids. Neurosteroids such as allopregnanolone are derived from cholesterol and have neuroprotective properties. In HD, reduced neurosteroid production may contribute to neuronal vulnerability.

β-Oxidation Impairment:
Fatty acid β-oxidation is impaired in HD, contributing to energy deficits. The mitochondria in HD show reduced capacity for fatty acid oxidation. This is particularly problematic in striatal medium spiny neurons with high energy demands. The combination of transcriptional repression and mitochondrial dysfunction creates severe energy deficits[@di2022].

Key Mechanisms:

• mHtt transcriptional repression of PPARγ and lipid genes
• Lipid droplet accumulation from impaired lipophagy
• Neurosteroid reduction affecting neuroprotection
• β-oxidation impairment causing energy deficits

Progressive Supranuclear Palsy

Lipid Abnormalities:
PSP shows lipid metabolism alterations in affected brain regions. Ganglioside composition changes have been reported in PSP brain. The distinctive tau pathology in PSP affects cellular lipid handling mechanisms. Cholesterol metabolism dysregulation contributes to oligodendrocyte dysfunction observed in PSP.

Key Mechanisms:

• Tau pathology affecting lipid metabolism
• Oligodendrocyte lipid dysfunction
• Ganglioside alterations

Key Proteins and Genes

| Protein/Gene | Function | Disease Association |
|-------------|----------|---------------------|
| [APOE](/genes/apoe) | Lipid transport, Aβ clearance | AD risk factor (ε4 allele) |
| [SREBP2](/genes/srebp2) (SREBF1) | Cholesterol synthesis regulation | Cholesterol dysregulation |
| [LXR](/genes/nr1h3) (LXRA) | Cholesterol efflux regulation | Therapeutic target |
| [ABCA1](/genes/abca1) | Cholesterol efflux to APOE | AD, ABCA1 deficiency worsens pathology |
| [ABCG1](/genes/abcg1) | Cholesterol efflux | Cholesterol homeostasis |
| [CYP27A1](/genes/cyp27a1) | 27-OHC production | AD, PD elevated |
| [CERS](/genes/cers2) | Ceramide synthesis | Ceramide elevation |
| [ASAH1](/genes/asah1) | Ceramide catabolism | Reduced in AD |
| [SPTLC](/genes/sptlc1) | Serine palmitoyltransferase | Sphingolipid synthesis |
| [PPARα](/genes/ppara) | FA oxidation regulation | HD transcriptional target |
| [PPARγ](/genes/pparg) | Lipid metabolism regulation | HD, AD impaired |
| [CPT](/genes/cpt1a) | β-Oxidation rate-limiting | FA metabolism |
| [FASN](/genes/fasn) | Fatty acid synthesis | Lipid droplets |

Cross-Links to Related Mechanisms

• [cGAS-STING Pathway in Neurodegeneration](/mechanisms/cgas-sting-neurodegeneration) — lipid peroxidation triggers cGAS-STING
• [Ferroptosis in Neurodegeneration](/mechanisms/ferroptosis-neurodegeneration) — lipid peroxidation in ferroptosis
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration) — β-oxidation impairment
• [Neuroinflammation in Neurodegeneration](/mechanisms/neuroinflammation-neurodegeneration) — lipid mediators in inflammation
• [Lipid Metabolism Dysfunction Comparison](/mechanisms/lipid-metabolism-dysfunction-comparison) — cross-disease comparison
• [Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein-pathology) — lipid interactions in PD
• [TREM2 Microglial Pathway](/mechanisms/trem2-microglial-pathway) — APOE and lipid clearance

Therapeutic Approaches

APOE-Directed Therapies

| Approach | Mechanism | Development Stage |
|----------|-----------|-------------------|
| APOE2 gene therapy | Enhanced lipid transport | Preclinical |
| APOE mimetic peptides | Lipid binding and clearance | Preclinical |
| ABCA1 agonists | Enhanced APOE lipidation | Preclinical |
| LXR agonists | Cholesterol efflux | Clinical trials |

Cholesterol-Targeting Approaches

| Approach | Mechanism | Development Stage |
|----------|-----------|-------------------|
| Statins | HMG-CoA reductase inhibition | Clinical trials (mixed results) |
| CYP27A1 inhibitors | Reduce 27-OHC | Preclinical |
| Cholesterol biosynthesis modulators | SREBP2 modulation | Preclinical |

Sphingolipid-Targeting Approaches

| Approach | Mechanism | Development Stage |
|----------|-----------|-------------------|
| Ceramide synthase inhibitors | Reduce ceramide levels | Preclinical |
| Ceramidase activators | Enhance ceramide catabolism | Preclinical |
| Ganglioside modulators | GM1/α-syn interaction | Preclinical |

Fatty Acid-Targeting Approaches

| Approach | Mechanism | Development Stage |
|----------|-----------|-------------------|
| DHA/EPA supplementation | Restore PUFA levels | Clinical trials |
| PPAR agonists | Enhance β-oxidation | Clinical trials |
| CPT agonists | Enhance FA oxidation | Preclinical |

Lipophagy Enhancement

| Approach | Mechanism | Development Stage |
|----------|-----------|-------------------|
| C9orf72 restoration | Enhance lipophagy | Gene therapy approaches |
| Progranulin restoration | Lysosomal function | Gene therapy approaches |
| Autophagy inducers | General autophagy enhancement | Clinical trials |

Lipid Metabolism in Brain Cell Types

Neurons

Neurons rely on lipid metabolism for:

• Synaptic vesicle formation and neurotransmitter release
• Membrane lipid bilayer maintenance
• Axonal myelin sheath support (in peripheral nervous system)
• Signaling molecule production (eicosanoids, endocannabinoids)

• High metabolic demands of neurotransmission
• Limited regenerative capacity
• Long axonal projections requiring extensive membrane synthesis

Astrocytes

Astrocytes are central to brain lipid metabolism:

• Synthesize and secrete APOE
• Provide lipids to neurons via APOE-containing lipoproteins
• Take up and process lipid droplets
• Respond to lipid peroxidation products

• Reduced lipid support to neurons
• Lipid droplet accumulation
• Impaired lipid recycling

Oligodendrocytes

Oligodendrocytes produce myelin lipids:

• Highest cholesterol content in brain
• Major phospholipid and galactolipid producers
• Vulnerable to lipid dysregulation

• Myelin breakdown in ALS, HD
• Iron accumulation in PSP
• Impaired lipid synthesis in white matter diseases

Microglia

Microglial lipid metabolism affects:

• Inflammatory lipid mediator production (prostaglandins, leukotrienes)
• Phagocytic clearance of lipid debris
• Lipid droplet accumulation in disease-associated microglia

Biomarkers

Blood-Based Lipid Biomarkers

| Biomarker | Disease | Change | Diagnostic Potential |
|-----------|---------|--------|---------------------|
| 27-Hydroxycholesterol | AD, PD | Elevated | Moderate |
| Apolipoprotein E isoforms | AD | APOE ε4 carriers show altered | High |
| Ceramides | AD, PD, ALS | Elevated | Moderate - disease-specific patterns |
| Phosphatidylcholines | Multiple | Altered ratios | Emerging |
| Oxysterols | AD, PD, HD | Elevated | Moderate |

Cerebrospinal Fluid Biomarkers

• Aβ-related lipids: Certain lipid species correlate with Aβ burden in AD
• Neurofilament light chain: Lipid changes parallel axonal damage markers
• Tau-associated lipids: Specific lipid profiles associate with tau pathology

Imaging Biomarkers

• MR spectroscopy: Detects lipid peaks in brain tissue
• Quantitative susceptibility mapping (QSM): Brain iron (related to lipid peroxidation)
• DTI: White matter integrity correlates with lipid status

Clinical Translation

Clinical Trial Data

| Agent | Target | Disease | Phase | NCT ID |
|-------|--------|---------|-------|--------|
| DHA supplementation | PUFA deficiency | AD | Phase 3 | NCT00440017 |
| LXR agonist (LGD-536926) | Cholesterol efflux | AD | Phase 1 | NCT03748706 |
| PPARγ agonist (pioglitazone) | Lipid metabolism | AD | Phase 3 | NCT01965756 |
| Statins (simvastatin) | Cholesterol synthesis | PD | Phase 3 | NCT02696642 |

Patient Selection

• Genetic stratification: APOE ε4 carriers for APOE-directed therapies
• Biomarker-driven: Lipid profiles for patient selection
• Disease stage: Early intervention likely more effective

Challenges

Summary

Lipid metabolism dysregulation represents a fundamental pathological feature across neurodegenerative diseases. Common mechanisms include:

While specific triggers differ (APOE, α-synuclein, C9orf72, tau/TDP-43, mutant huntingtin), downstream lipid changes converge on shared pathways affecting neuronal survival. Understanding these shared mechanisms provides opportunities for common therapeutic interventions targeting lipid metabolism.

The growing recognition of lipid metabolism as a central driver of neurodegeneration offers hope for new therapeutic approaches. Future directions include combination therapies targeting multiple lipid pathways, gene therapy approaches, and personalized medicine based on genetic stratification.

References

See Also

Related Hypotheses:

• [Tau-Independent Microtubule Stabilization via MAP6 Enhancement](/hypotheses/h-e12109e3)
• [Perforant Path Presynaptic Terminal Protection Strategy](/hypotheses/h-76888762)
• [Reelin-Mediated Cytoskeletal Stabilization Protocol](/hypotheses/h-d2df6eaf)
• [HCN1-Mediated Resonance Frequency Stabilization Therapy](/hypotheses/h-d40d2659)
• [Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioenergetics](/hypotheses/h-5ff6c5ca)